Skip to main content
. 2022 Dec 21;46(3):519–525. doi: 10.2337/dc22-1728

Table 1.

Baseline characteristics at Look AHEAD enrollment by baseline HbA1c categories***

Baseline characteristic Baseline HbA1c (%)
<7.0 (53 mmol/mol) (N = 1,944) 7.0–7.9 (N = 1,310) ≥8.0 (64 mmol/mol) (N = 915) P value*
Age, years (%)
 45–54 (23.1) 390 (20.1) 288 (22.0) 291 (31.8) <0.001
 55–64 (56.9) 1,138 (58.5) 737 (56.3) 499 (54.5)
 65–76 (19.8) 416 (21.4) 285 (21.8) 125 (13.7)
Sex (%)
 Female (59.1) 1,131 (58.2) 785 (59.9) 549 (60.0) 0.51
 Male (40.9) 813 (41.8) 525 (40.1) 366 (40.0)
BMI, kg/m2 (%)
 25–29 (15.2) 330 (17.0) 183 (14.0) 121 (13.2) 0.01
 30–39 (62.6) 1,215 (62.5) 824 (62.9) 571 (62.4)
 ≥40 (22.2) 399 (20.5) 303 (23.1) 223 (24.4)
Diabetes duration, years (%) (missing = 27)
 0–4 (46.6) 1,149 (59.5) 513 (39.5) 267 (29.2) <0.001
 ≥5 (53.4) 782 (40.5) 785 (60.5) 646 (70.8)
Diabetes medication (%) (missing = 41)
 Insulin (14.9) 132 (6.9) 225 (17.4) 257 (28.2) <0.001
 Metformin/no insulin (52.4) 991 (51.5) 704 (54.4) 468 (51.4)
 Other medications/no insulin (18.8) 403 (21.0) 231 (17.8) 144 (15.8)
 No medication (13.9) 397 (20.6) 135 (10.4) 41 (4.5)
History of CVD (%)**
 No (86.9) 1,714 (88.2) 1,123 (85.7) 785 (85.8) 0.07
 Yes (13.1) 230 (11.8) 187 (14.3) 130 (14.2)
Intervention group (%)
 DSE (49.3) 947 (48.7) 656 (50.1) 453 (49.5) 0.74
 ILI (50.7) 997 (51.3) 654 (49.9) 462 (50.5)
FI 19.93 (0.15) 20.82 (0.19) 21.53 (0.22) <0.001

Data are N (% of column) or mean (SE) unless otherwise indicated.

*

χ2 test or ANOVA.

**

History of cardiovascular disease: self-report of prior myocardial infarction, coronary artery bypass, angioplasty/stent procedures, peripheral vascular disease, stroke, stable angina, or class I/II heart failure.

***

N = 5 participants included in our analysis files did not have records of a baseline HbA1c and did not contribute to this table.